The Bank of Canada completed its first resolution plan for the Canadian Derivatives and Clearing Corporation (CDCC) in 2024.

Booking's valuation has dropped, creating a safer buying opportunity with a current FY25 P/E multiple of ~20x. Read more ...

Lam Research remains a strong long-term investment in the semiconductor space, driven by AI infrastructure growth and a broad ...

Q4 2024 Earnings Call Transcript March 13, 2025 Operator: Good morning, everyone. Thank you for joining Acacia Research’s ...

Our new build program is also expected to be substantially completed in 2025. We believe the Company’s current share price does not reflect the strength of our business and that a share repurchase ...

Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

VAALCO Energy, Inc. (NYSE: EGY, LSE: EGY) ("Vaalco" or the "Company") today reported operational and financial results for the fourth quarter and full year of 2024 and year-end 2024 reserves. The ...

TORONTO, March 13, 2025 (GLOBE NEWSWIRE) -- Mount Logan Capital Inc. (Cboe Canada: MLC) ("Mount Logan” or the "Company”) ...

The new data provides evidence of the benefit of Idorsia's dual orexin receptor antagonist, daridorexant (QUVIVIQ™), at a ...